Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome.

Abstract

Nine patients with pancreatic apudomas (seven gastrinomas, one glucagonoma, one tumor secreting a substance P-like component) and nine with metastasized carcinoid tumors were treated with a somatostatin analogue (SMS 201-995), administered subcutaneously twice daily for 3 days. Treatment was pursued for 2 to 12 months in nine patients in whom SMS was clinically and/or biologically beneficial. In gastrinomas, SMS decreased plasma gastrin in all but one patient, inhibited the residual gastric acid secretion under H2-blockers and improved diarrhea; in the glucagonoma patient, glucagonemia decreased and skin lesions disappeared. In carcinoid syndrome, clinical efficacy was partial and inconstant; daily 5-hydroxyindole acetic acid (5-HIAA) output was slightly decreased. Plasma substance P levels decreased in six patients with initially high concentrations. No antitumoral activity or side effects have been so far evidenced. SMS 201-995 is a useful, well-tolerated agent in secreting pancreatic apudomas and to a lesser extent in carcinoid syndrome, where high-dosage regimens may be required.

• Authors: J C Souquet, G Sassolas, J Forichon, P Champetier, C Partensky, J A Chayvialle
• Journal: Cancer (Cancer) Vol. 59 Issue 9 Pg. 1654-60 (May 01 1987) ISSN: 0008-543X [Print] United States
• PMID: 2435403 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Gastrins
• Substance P
• Somatostatin
• Octreotide

Topics

• Adult
• Aged
• Carcinoid Tumor (drug therapy)
• Female
• Gastric Juice (metabolism)
• Gastrins (blood)
• Glucagonoma (drug therapy)
• Humans
• Hydrogen-Ion Concentration
• Male
• Middle Aged
• Octreotide
• Pancreatic Neoplasms (drug therapy)
• Somatostatin (analogs & derivatives, therapeutic use)
• Substance P (metabolism)
• Zollinger-Ellison Syndrome (drug therapy)